Claims for Patent: 12,280,151

Summary for Patent: 12,280,151

Title:	Synthetic progestogens and pharmaceutical compositions comprising the same
Abstract:	Described herein are synthetic progestogens, such as 6β, 7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Inventor(s):	Philippe Perrin, Jose Luis Velada, Dominique Drouin
Assignee:	Laboratorios Leon Farma SA
Application Number:	US18/765,167
Patent Claims:	1. A pharmaceutical composition in the form of a tablet, comprising: 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, and one or more pharmaceutically acceptable excipients, wherein the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone is present in the pharmaceutical composition in an amount of 4 milligrams (mg); and wherein the pharmaceutical composition is formulated such that: (1) when one tablet is orally administered to a patient under fasting conditions, the pharmaceutical composition provides a pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprising: (i) a mean Tmaxranging from 2.2 hours to 6 hours; (ii) a mean Cmax which is less than 30 ng/ml; and (iii) a mean AUC0h-tlast of at least 300 ng*h/ml; and (2) no more than 50% of the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 30 minutes when the tablet is subjected to an in vitro dissolution test according to the USP XXIII Paddle Method performed in 900 mL of water at 37° C. (±0.5° C.) using a USP dissolution test apparatus 2 at a stirring rate of 50 rpm; and wherein the pharmaceutical composition does not comprise estrogen. 2. The pharmaceutical composition of claim 1, wherein the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises particles having a diameter less than 200 microns (μm) as determined by volume-based particle size measurement. 3. The pharmaceutical composition of claim 2, wherein the particles have a diameter of less than 200 microns (μm) as determined by laser diffraction in a wet dispersion in water. 4. The pharmaceutical composition of claim 1, wherein the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises particles having a median particle size ranging from 10 micrometers (μm) to 60 μm as determined by volume-based particle size measurement. 5. The pharmaceutical composition of claim 4, wherein the particles have a median particle size ranging from 10 μm to 60 μm as determined by laser diffraction in a wet dispersion in water. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated such that at least 50% of the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 4 hours when subjected to the in vitro dissolution test according to the USP XXIII Paddle Method performed in 900 mL of water at 37° C. (±0.5° C.) using a USP dissolution test apparatus 2 at a stirring rate of 50 rpm. 7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated such that at least 55% of the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 4 hours when subjected to the in vitro dissolution test according to the USP XXIII Paddle Method performed in 900 mL of water at 37° C. (±0.5° C.) using a USP dissolution test apparatus 2 at a stirring rate of 50 rpm. 8. The pharmaceutical composition of claim 1, wherein the pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21, 17-carbolactone comprises an AUC0h-tlast of at least 350 ng*h/ml. 9. The pharmaceutical composition of claim 1, wherein the pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises a mean Cmax ranging from 15 ng/ml to less than 30 ng/ml. 10. The pharmaceutical composition of claim 1, wherein the pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises a mean tmax ranging from 3.0 hours to 4.0 hours. 11. The pharmaceutical composition of claim 8, wherein the pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises a mean Cmax ranging from 15 ng/ml to less than 30 ng/ml. 12. The pharmaceutical composition of claim 11, wherein the pharmacokinetic profile for the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises a mean tmax ranging from 3.0 hours to 4.0 hours. 13. The pharmaceutical composition of claim 12, wherein the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises particles having a diameter less than 200 microns (μm) as determined by volume-based particle size measurement. 14. The pharmaceutical composition of claim 13, wherein the particles have a diameter of less than 200 microns (μm) as determined by laser diffraction in a wet dispersion in water. 15. The pharmaceutical composition of claim 12, wherein the 6β,7β:15β, 16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprises particles having a median particle size ranging from 10 micrometers (μm) to 60 μm as determined by volume-based particle size measurement. 16. The pharmaceutical composition of claim 15, wherein the particles have a median particle size ranging from 10 μm to 60 μm as determined by laser diffraction in a wet dispersion in water.